LQDA Liquidia Corporation
LQDA Liquidia Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $25.68 · VWAP $41.39 · +87.7% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
LQDA Price Structure
Loading timeframes…
Peers
Every watchlist LQDA belongs to, members best 30-day change first — LQDA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Decision history
2 scored calls · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported EPS $0.74 versus analyst consensus of $0.84 (-11.5%).
full note →Against street estimates
How LQDA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about LQDA from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
LQDA research tape
29 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.